The majority of driver mutations are targetable by the EGFR tyrosine kinase inhibitors (TKIs) (e.g. gefitinib, erlotinib, afatinib, and osimertinib in EGFR-mutant NSCLC; crizotinib, ceritinib, brigatinib, lorlatinib, and alectinib in ALK rearranged tumours; crizotinib in ROS1 rearranged disease). Here, EGFR is linked to non-small cell lung carcinoma.